Cargando…
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma
Visfatin is considered a pro-inflammatory adipocytokine, and it is commonly increased in obesity-related diseases. This study aimed to evaluate the levels of serum visfatin in patients with hepatocellular carcinoma (HCC) and its diagnostic and predictive value in detecting HCC. Fasting serum levels...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410315/ https://www.ncbi.nlm.nih.gov/pubmed/28178643 http://dx.doi.org/10.18632/oncotarget.15080 |
_version_ | 1783232654363066368 |
---|---|
author | Sun, Yifan Zhu, Shengbo Wu, Zhitong Huang, Yiyong Liu, Chunming Tang, Shifu Wei, Lili |
author_facet | Sun, Yifan Zhu, Shengbo Wu, Zhitong Huang, Yiyong Liu, Chunming Tang, Shifu Wei, Lili |
author_sort | Sun, Yifan |
collection | PubMed |
description | Visfatin is considered a pro-inflammatory adipocytokine, and it is commonly increased in obesity-related diseases. This study aimed to evaluate the levels of serum visfatin in patients with hepatocellular carcinoma (HCC) and its diagnostic and predictive value in detecting HCC. Fasting serum levels of visfatin of 135 HCC patients, 115 chronic hepatitis B (CHB) patients, 129 liver cirrhosis (LC) patients, and 149 healthy controls were determined via enzyme-linked immunosorbent assay. Meanwhile, serum alpha fetal protein (AFP) and interleukin-6 (IL-6) were also assayed. The median serum visfatin concentration in HCC patients was 1.113 ng/mL (range: 0.823-2.214 ng/mL), which was significant higher than those of healthy controls, CHB patients, and LC patients (P<0.05). The serum visfatin concentration in HCC patients was positively correlated with AFP (r=0.595, P<0.001) and IL-6 (r=0.261, P<0.015) and was also associated with tumor size and tumor node metastasis stage. Moreover, elevated levels of serum visfatin were associated with a higher HCC risk for CHB and LC patients. Multivariate Cox regression analysis had shown that HCC patients with high levels of serum visfatin had significantly shorter overall survival times than those with low serum visfatin levels (P<0.001). Using a cutoff visfatin level of 1.403 ng/mL, the receiver operating characteristic curve analysis showed unappealing sensitivity and specificity values (45.76% and 74.79%, respectively; AUC=0.626) regarding visfatin's use as a diagnostic marker for HCC. Our results indicate that increased serum visfatin levels are associated with poor prognosis of HCC. Visfatin may be a potential therapeutic target of HCC. |
format | Online Article Text |
id | pubmed-5410315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54103152017-05-04 Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma Sun, Yifan Zhu, Shengbo Wu, Zhitong Huang, Yiyong Liu, Chunming Tang, Shifu Wei, Lili Oncotarget Research Paper Visfatin is considered a pro-inflammatory adipocytokine, and it is commonly increased in obesity-related diseases. This study aimed to evaluate the levels of serum visfatin in patients with hepatocellular carcinoma (HCC) and its diagnostic and predictive value in detecting HCC. Fasting serum levels of visfatin of 135 HCC patients, 115 chronic hepatitis B (CHB) patients, 129 liver cirrhosis (LC) patients, and 149 healthy controls were determined via enzyme-linked immunosorbent assay. Meanwhile, serum alpha fetal protein (AFP) and interleukin-6 (IL-6) were also assayed. The median serum visfatin concentration in HCC patients was 1.113 ng/mL (range: 0.823-2.214 ng/mL), which was significant higher than those of healthy controls, CHB patients, and LC patients (P<0.05). The serum visfatin concentration in HCC patients was positively correlated with AFP (r=0.595, P<0.001) and IL-6 (r=0.261, P<0.015) and was also associated with tumor size and tumor node metastasis stage. Moreover, elevated levels of serum visfatin were associated with a higher HCC risk for CHB and LC patients. Multivariate Cox regression analysis had shown that HCC patients with high levels of serum visfatin had significantly shorter overall survival times than those with low serum visfatin levels (P<0.001). Using a cutoff visfatin level of 1.403 ng/mL, the receiver operating characteristic curve analysis showed unappealing sensitivity and specificity values (45.76% and 74.79%, respectively; AUC=0.626) regarding visfatin's use as a diagnostic marker for HCC. Our results indicate that increased serum visfatin levels are associated with poor prognosis of HCC. Visfatin may be a potential therapeutic target of HCC. Impact Journals LLC 2017-02-04 /pmc/articles/PMC5410315/ /pubmed/28178643 http://dx.doi.org/10.18632/oncotarget.15080 Text en Copyright: © 2017 Sun et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Sun, Yifan Zhu, Shengbo Wu, Zhitong Huang, Yiyong Liu, Chunming Tang, Shifu Wei, Lili Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma |
title | Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma |
title_full | Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma |
title_fullStr | Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma |
title_full_unstemmed | Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma |
title_short | Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma |
title_sort | elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410315/ https://www.ncbi.nlm.nih.gov/pubmed/28178643 http://dx.doi.org/10.18632/oncotarget.15080 |
work_keys_str_mv | AT sunyifan elevatedserumvisfatinlevelsareassociatedwithpoorprognosisofhepatocellularcarcinoma AT zhushengbo elevatedserumvisfatinlevelsareassociatedwithpoorprognosisofhepatocellularcarcinoma AT wuzhitong elevatedserumvisfatinlevelsareassociatedwithpoorprognosisofhepatocellularcarcinoma AT huangyiyong elevatedserumvisfatinlevelsareassociatedwithpoorprognosisofhepatocellularcarcinoma AT liuchunming elevatedserumvisfatinlevelsareassociatedwithpoorprognosisofhepatocellularcarcinoma AT tangshifu elevatedserumvisfatinlevelsareassociatedwithpoorprognosisofhepatocellularcarcinoma AT weilili elevatedserumvisfatinlevelsareassociatedwithpoorprognosisofhepatocellularcarcinoma |